Methylphenidate Improves Apathy in Veterans with Alzheimer’s

by U.S. Medicine

November 9, 2017

LITTLE ROCK—Apathy is a common behavioral problem in Alzheimer’s disease and can lead to everything from functional impairment to higher medical costs to increased mortality.

A study published in the American Journal of Psychiatry reports on a promising new treatment, however. A team led by researchers from the Central Arkansas Veterans’ Healthcare System and the University of Arkansas investigated the effect on the drug methylphenidate for the condition.1

The 12-week, prospective, double-blind, randomized, placebo-controlled trial comparing methylphenidate vs. placebo was conducted in 60 community-dwelling veterans with mild Alzheimer’s disease. All participants were male with an average age of 77.

Apathy, the primary outcome, was determined using the Apathy Evaluation Scale–Clinician, while the secondary outcome, cognition was measured using the Mini-Mental State Examination, Modified Mini-Mental State Examination. The study also looked at functional status, improvement and severity and depression rates, with all indicators measured at baseline and four, eight and 12 weeks.

Results indicate that, after adjusting for baseline, the methylphenidate group had significantly greater improvement in apathy than the placebo group at four weeks, eight weeks and 12 weeks. By the final measurement, study authors also note greater improvement in cognition, functional status, caregiver burden, Clinical Global Impressions Scale scores and depression in the methylphenidate group compared with the placebo group.

“Methylphenidate improved apathy in a group of community-dwelling veterans with mild Alzheimer’s disease,” the researchers concluded. “Methylphenidate also improved cognition, functional status, caregiver burden, CGI scores, and depression.”

  1. Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, et. al. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer’s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2017 Sep 15:appiajp201717030316. doi: 10.1176/appi.ajp.2017.17030316. [Epub ahead of

print] PubMed PMID: 28945120.

Comments are closed here.

Related Articles

Pharmacist Medication Management Helps Diabetic Veterans, Physicians

HINES, IL—Older age, obesity and Agent Orange exposure create a trifecta of diabetes risk for the VA. Nearly 25% of veterans have diabetes, making efficient and effective management of their care a top concern for... View Article

VA Facing Critical Healthcare Staffing Shortages in Near Future

Replacing Retirees Hampered by Lower Salaries WASHINGTON—Oversight agencies are sounding the alarm that VA is plagued with large staffing shortages in critical areas, including physicians, registered nurses, physician assistants, psychologists and physical therapists, as well... View Article

U.S. Medicine Recommends

More From alzheimersdementia


TBI Might Not Be a Risk Factor for Alzheimer’s Disease

BOSTON—New research is calling into question whether traumatic brain injury is actually a risk factor for Alzheimer’s disease. A report in the journal Alzheimer’s & Dementia discussed recent research with neuropathologic or biomarker evidence of... View Article


Veterans Treated by VA Often Have Risk Factors for Elder Abuse

The VHA should take a lead role in combatting elder abuse, which affects at least 10% of older adults in the United States, according to a recent medical journal article.


Study: Alzheimer’s Disease Blood Test Would Be Feasible

LOS ANGELES — A new study provides the first evidence that a simple blood test could be developed to confirm the presence of beta amyloid proteins in the brain, which could help in early diagnosis... View Article


Treatment Tested to Break TBI-Alzheimer’s Link

FRANKFORT, KY — The cascade of events following mild traumatic brain injury (mTBI) appears to increase the risk for developing a progressive degenerative brain disease, and researchers now are testing a treatment that might interrupt... View Article


VA Study: Vitamin E 'Significantly' Slows Alzheimer's Disease Functional Decline

By Brenda L. Mooney MINNEAPOLIS — Could a vitamin found on drugstore shelves be effective in slowing cognitive decline for patients with Alzheimer’s disease? New VA research found that a daily dose of 2,000 IUs... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up